Syndax Pharmaceuticals (Syndax Pharmaceuticals) Price-to-Tangible-Book

: 3.20 (As of Today)

View and export this data going back to 2016. Start your Free Trial

As of today (2024-04-24), Syndax Pharmaceuticals's share price is $20.89. Syndax Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $6.53. Hence, Syndax Pharmaceuticals's Price to Tangible Book Ratio of today is 3.20.

The historical rank and industry rank for Syndax Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

SNDX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.55 Med: 3.13 Max: 7.54
Current: 3.2

During the past 12 years, Syndax Pharmaceuticals's highest Price to Tangible Book Ratio was 7.54. The lowest was 1.55. And the median was 3.13.

SNDX's Price-to-Tangible-Book is ranked worse than
57.55% of 1218 companies
in the Biotechnology industry
Industry Median: 2.69 vs SNDX: 3.20

A closely related ratio is called PB Ratio. As of today, Syndax Pharmaceuticals's share price is $20.89. Syndax Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $6.53. Hence, Syndax Pharmaceuticals's P/B Ratio of today is 3.20.

Syndax Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Syndax Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syndax Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

7.54

4.22

2.95

3.71

3.31

Syndax Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															3.71	3.32	3.63	2.82	3.31

Competitive Comparison

For the Biotechnology subindustry, Syndax Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syndax Pharmaceuticals Price-to-Tangible-Book Distribution

For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Syndax Pharmaceuticals's Price-to-Tangible-Book falls into.

Syndax Pharmaceuticals Price-to-Tangible-Book Calculation

Syndax Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	20.89	/	6.533
	=	3.20

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Syndax Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Syndax Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Syndax Pharmaceuticals (Syndax Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (NAS:SNDX) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

1T3:Germany

Address

35 Gatehouse Drive, Building D, Floor 3, Waltham, MA, USA, 02451

Website

https://www.syndax.com

Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.

Executives

Briggs Morrison	director, officer: Chief Executive Officer	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
William Meury	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Keith A. Goldan	officer: Chief Financial Officer	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Neil Gallagher	officer: President, Head of R&D	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Peter Ordentlich	officer: Chief Technology Officer	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 140, WALTHAM MA 02451
Michael A Metzger	officer: President and COO	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Steve M Sabus	officer: Chief Commercial Officer	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Keith Katkin	director	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Dennis Podlesak	director	C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Catherine Madigan	officer: Chief Medical Officer	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Alexander Nolte	officer: Chief Accounting Officer	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Fabrice Egros	director	C/O SYNDAX PHARMACEUTICALS, INC., TOTTEN POND ROAD, SUITE 140, WALTHAM MA 02451
Huber Martin H. Jr.	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Daphne Karydas	officer: Chief Financial Officer	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451